ADIPOQ and chronic kidney disease: Provided that we included patients with CKD for the analysis in which condition of the clearance of serum adiponectin is affected, it is speculated that the nadir point of serum adiponectin for the risk of adverse CV outcomes in the current study is modified along with the alteration in the overall association between serum adiponectin level and the risk of CV events.